for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

FibroGen Inc

FGEN.OQ

Latest Trade

40.84USD

Change

0.94(+2.36%)

Volume

190,752

Today's Range

40.27

 - 

41.23

52 Week Range

33.51

 - 

61.95

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
39.90
Open
40.27
Volume
190,752
3M AVG Volume
12.10
Today's High
41.23
Today's Low
40.27
52 Week High
61.95
52 Week Low
33.51
Shares Out (MIL)
86.92
Market Cap (MIL)
3,467.95
Forward P/E
-115.95
Dividend (Yield %)
--

Next Event

Q3 2019 FibroGen Inc Earnings Release

Latest Developments

More

Fibrogen Says Evrenzo Approved By Japan’s Ministry of Health, Labour and Welfare

Astellas Pharma Says Japan's Ministry Of Health, Labour And Welfare Approved Evrenzo(Roxadustat)

Roxadustat Approved In China For Treatment Of Anemia In Chronic Kidney Disease Patients Not Receiving Dialysis

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About FibroGen Inc

FibroGen, Inc. is a science-based biopharmaceutical company discovering and developing a pipeline of first- in-class therapeutics. The Company is focused on fibrosis and hypoxia-inducible factor (HIF) biology and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer. Roxadustat, the Company’s most advanced product candidate, is an oral small molecule inhibitor of HIF prolyl hydroxylase activity in Phase III clinical development for the treatment of anemia in chronic kidney disease (CKD), and is entering Phase III development for anemia in lower risk myelodysplastic syndromes (MDS). The Company has developed Pamrevlumab. Pamrevlumab is a proprietary therapeutic antibody to inhibit the activity of connective tissue growth factor (CTGF), a common factor in chronic fibrotic and proliferative disorders characterized by persistent and excessive scarring that can lead to organ dysfunction and failure.

Industry

Biotechnology & Drugs

Contact Info

409 Illinois St

+1.415.9781200

http://www.fibrogen.com

Executive Leadership

James A. Schoeneck

Interim Chief Executive Officer, Director

Pat Cotroneo

Chief Financial Officer

Kin-Hung Peony Yu

Chief Medical Officer

Thomas F. Kearns

Lead Independent Director

Suzanne Blaug

Independent Director

Key Stats

1.88 mean rating - 8 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.2K

2017

0.1K

2018

0.2K

2019(E)

0.3K
EPS (USD)

2016

-0.980

2017

-1.730

2018

-1.030

2019(E)

-0.344
Price To Earnings (TTM)
83.58
Price To Sales (TTM)
9.84
Price To Book (MRQ)
5.51
Price To Cash Flow (TTM)
54.93
Total Debt To Equity (MRQ)
11.77
LT Debt To Equity (MRQ)
9.85
Return on Investment (TTM)
6.23
Return on Equity (TTM)
5.49

Latest News

China first to approve AstraZeneca, FibroGen anaemia drug

China has become the first country to approve a new anaemia drug from AstraZeneca and FibroGen, well before decisions by regulators in the United States or Europe.

BRIEF-FibroGen Reports Q1 Loss Per Share $0.50

* Q1 EARNINGS PER SHARE VIEW $-0.51 -- THOMSON REUTERS I/B/E/S

BRIEF-Fibrogen Inc CEO's 2017 Compensation Was $7.1 Million

* FIBROGEN INC SAYS CEO THOMAS B. NEFF'S 2017 TOTAL COMPENSATION WAS $7.1 MILLION VERSUS $5.2 MILLION IN 2016 – SEC FILING Source text (https://bit.ly/2Hpk39x) Further company coverage:

BRIEF-FibroGen Gets FDA Fast Track Designation For Its Pancreatic Cancer Treatment

* UPDATE - FIBROGEN GRANTED FAST TRACK DESIGNATION BY U.S. FDA FOR PAMREVLUMAB TREATMENT OF PATIENTS WITH LOCALLY ADVANCED UNRESECTABLE PANCREATIC CANCER

BRIEF-Fibrogen Granted Fast Track Designation By U.S. FDA For Pamrevlumab Treatment Of Patients

* FIBROGEN GRANTED FAST TRACK DESIGNATION BY U.S. FDA FOR PAMREVLUMAB TREATMENT OF PATIENTS WITH LOCALLY ADVANCED UNRESECTABLE PANCREATIC CANCER Source text for Eikon: Further company coverage: (Reuters.Brief@thomsonreuters.com)

BRIEF-FibroGen Q4 Loss Per Share $0.27

* FIBROGEN REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS

BRIEF-Fibrogen Inc reports Q3 loss per share $0.50

* Q3 earnings per share view $-0.37 -- Thomson Reuters I/B/E/S

BRIEF-Fibrogen announces acceptance by china FDA of roxadustat NDA for treatment of anemia associated with dialysis and non-dialysis kidney disease

* Fibrogen announces acceptance by china FDA of roxadustat new drug application (NDA) for treatment of anemia associated with dialysis and non-dialysis chronic kidney disease (CKD)

BRIEF-Fibrogen's ‍Pamrevlumab was well tolerated with no safety risks

* Announced results from co's phase 2b randomized, double-blind, placebo-controlled study in patients with idiopathic pulmonary fibrosis

BRIEF-Fibrogen announces pricing of follow-on offering of common stock

* Fibrogen, Inc. announces pricing of follow-on offering of common stock

BRIEF-FibroGen announces proposed follow-on offering of common stock

* Fibrogen Inc announces proposed follow-on offering of common stock

BRIEF-Fibrogen ‍net loss per diluted share for quarter ended June 30 was $0.48

* Fibrogen Inc - net loss per basic and diluted share for quarter ended June 30, 2017 was $0.48 - SEC filing

BRIEF-Fibrogen Inc reports Q2 loss per share $0.48

* Q2 earnings per share view $-0.47 -- Thomson Reuters I/B/E/S

BRIEF-Fibrogen reports Q1 loss per share $0.52

* Q1 earnings per share view $-0.49 -- Thomson Reuters I/B/E/S

BRIEF-Fibrogen reports pricing of follow-on offering of common stock

* Fibrogen, Inc. announces pricing of follow-on offering of common stock

BRIEF-Fibrogen wins China clearance to conduct key study testing roxadustat

* Fibrogen announces china fda approval of cta to conduct pivotal phase 2/3 clinical trial of roxadustat in anemia associated with lower risk mds

BRIEF-Fibrogen Inc files for potential mixed shelf offering

* Fibrogen Inc files for potential mixed shelf offering; size not disclosed Source text:(http://bit.ly/2mGofE4) Further company coverage:

BRIEF-Fibrogen reports fiscal 2016 financial results

* Sees to report pamrevlumab topline phase 2 ipf data, placebo-controlled and combination treatment sub-study results, in q3

BRIEF-FibroGen's Roxadustat (FG-4592) meets primary endpoints in two phase 3 anemia studies in China

* FibroGen's Roxadustat (FG-4592) meets primary endpoints in two phase 3 anemia studies in China

BRIEF-Fibrogen reports Q3 loss per share $0.38

* Fibrogen reports financial results for the third quarter of 2016 and provides corporate update

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up